StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Pfizer CentreOne (Contract Development & Manufacturing by Quarter

Pfizer CentreOne (Contract Development & Manufacturing Organization — CDMO) — Worldwide reported YoY (%) (%)

QuarterlyAnnual

Pfizer Pfizer CentreOne (Contract Development & Manufacturing: 7.0% in Q2 2026, down 11.0 pts from a year earlier.

Latest, Q2 2026
7.0%
Period ended Jun 28, 2026
Change on a year earlier
-11.0 pts
18.0% in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

“|| PFIZER CENTREONE (i) | $ | 373 | $ | 348 | 7% | 5% | $ | 67 | $ | 101 | (34%) | $ | 306 | $ | 247 | 24% | 21%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPfizer CentreOne (Contract Development & Manufacturing Organization — CDMO) — Worldwide reported YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 20267.0%-11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 20266.0%–Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202526.0%+37.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202521.0%+24.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202518.0%+28.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q4 2024Dec 31, 2024-11.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 2024-3.0%+5.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 2024-10.0%-6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-16.0%-6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q3 2023Oct 1, 2023-8.0%+31.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 2023-4.0%+23.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 2023-10.0%+3.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022-4.0%-28.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 2022-39.0%–Form 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 2022-27.0%-122.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗
Q1 2022Apr 3, 2022-13.0%–Form 8-K (Earnings / Guidance Release) (pfe-04032022xex99.htm, filed 2022-05-03) ↗

Cite this data

StockData. (2026). Pfizer Pfizer CentreOne (Contract Development & Manufacturing (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/pc1-yoy-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.